Lipigon Pharmaceuticals AB announced positive top-line results from a phase I SAD study of its investigational medicine Lipisense in healthy volunteers. Lipisense is an RNA drug candidate developed to lower blood lipid triglycerides in patients with severely elevated levels by preventing the production of the protein ANGPTL4. Lipigon reports that the phase I SAD (Single Ascending Dose) study demonstrated that Lipisense has a favorable safety and pharmacokinetic profile.

Lipisense was well tolerated, with no serious adverse events reported. The SAD part included 20 healthy study participants, and the primary goal was to evaluate safety and tolerability after an injection of Lipisense at three different dose levels or placebo. Since no serious adverse effects were reported, the company has also decided to add a fifth cohort of healthy subjects at a 72 mg dose in the SAD study.